Equity Details
Price & Market Data
Price: $107.9
Daily Change: +$3.34 / 3.10%
Daily Range: $102.1 - $107.9
Market Cap: $8,100,446,208
Daily Volume: 673,853
Performance Metrics
1 Week: 1.05%
1 Month: -1.11%
3 Months: 0.45%
6 Months: 9.84%
1 Year: 39.26%
YTD: 1.94%
About Nuvalent, Inc. (NUVL)
In-depth market report for Nuvalent, Inc. (NUVL). The stock is valued at 107.9, with a daily change of +$3.34 / 3.10%. Market cap: 8,100,446,208. All key performance metrics are updated, including YTD and 52-week returns.
Company Details
Employees: 228
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.